iBio (IBIO) EBITDA Margin (2011 - 2025)

iBio (IBIO) has 15 years of EBITDA Margin data on file, last reported at 5951.0% in Q3 2025.

• On a quarterly basis, EBITDA Margin changed N/A year-over-year to 5951.0% in Q3 2025; TTM through Mar 2026 was 9653.0%, a 516953.0% decrease from a year earlier, with the FY2025 full-year figure at 4650.5%, up 274239.0% from the prior year.
• EBITDA Margin for Q3 2025 stood at 5951.0%, down from 2599.0% in the prior quarter.
• Over the last five years, EBITDA Margin for IBIO reached as high as 377.11% in Q1 2022 and fell as low as 10206.0% in Q3 2023.
• Historically, EBITDA Margin has averaged 3597.2% across 5 years, with a median of 2209.5% in 2024.
• On a YoY basis, EBITDA Margin climbed as much as 329176 bps in 2021 and fell as far as 453146 bps in 2021.
• Year by year, EBITDA Margin stood at 6220.24% in 2021, then jumped by 94 bps to 377.11% in 2022, then slumped by 2606 bps to 10206.0% in 2023, then jumped by 78 bps to 2209.5% in 2024, then plunged by 169 bps to 5951.0% in 2025.
• Per Business Quant data, the three most recent EBITDA Margin figures were 5951.0% in Q3 2025, 2599.0% in Q2 2025, and 2209.5% in Q4 2024.